litlas
ログインアカウント作成

Do‐Youn Oh

2004–2025 年に発表

別表記
Do-Youn Oh · Do Youn Oh
216
論文数
37,134
被引用数
84
h 指数
198
i10 指数

被引用数

Do‐Youn Oh の年別被引用数1984 年: 被引用 1 件1997 年: 被引用 1 件1999 年: 被引用 3 件2000 年: 被引用 1 件2001 年: 被引用 1 件2005 年: 被引用 17 件2006 年: 被引用 51 件2007 年: 被引用 39 件2008 年: 被引用 37 件2009 年: 被引用 35 件2010 年: 被引用 46 件2011 年: 被引用 52 件2012 年: 被引用 35 件2013 年: 被引用 111 件2014 年: 被引用 114 件2015 年: 被引用 119 件2016 年: 被引用 120 件2017 年: 被引用 169 件2018 年: 被引用 216 件2019 年: 被引用 778 件2020 年: 被引用 1,441 件2021 年: 被引用 1,820 件2022 年: 被引用 1,722 件2023 年: 被引用 1,445 件2024 年: 被引用 2,958 件2025 年: 被引用 1,725 件2026 年: 被引用 37 件1985〜1996 年は被引用が無いため表示していません1998 年は被引用が無いため表示していません2002〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,538 件、この内訳の 21.8%中国: 引用元論文 2,437 件、この内訳の 15%イタリア: 引用元論文 1,073 件、この内訳の 6.6%日本: 引用元論文 980 件、この内訳の 6%イギリス: 引用元論文 834 件、この内訳の 5.1%ドイツ: 引用元論文 801 件、この内訳の 4.9%フランス: 引用元論文 620 件、この内訳の 3.8%スペイン: 引用元論文 607 件、この内訳の 3.7%韓国: 引用元論文 601 件、この内訳の 3.7%カナダ: 引用元論文 447 件、この内訳の 2.8%オランダ: 引用元論文 370 件、この内訳の 2.3%スイス: 引用元論文 310 件、この内訳の 1.9%
0%21.8%その他 22.4%

機関

分野

  • Medicine76.8%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Immunology and Microbiology3%
  • Materials Science0.6%
  • Engineering0.5%
  • Neuroscience0.4%
  • その他1.4%

トピック

  • Cancer Immunotherapy and Biomarkers6.3%
  • Pancreatic and Hepatic Oncology Research6%
  • HER2/EGFR in Cancer Research5%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.4%
  • Gastric Cancer Management and Outcomes3.2%
  • Monoclonal and Polyclonal Antibodies Research2.8%
  • その他72.3%

共著者

全論文

検索で開く
  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    著者: Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee - Journal of Clinical Oncology 2023 被引用: 931

  2. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    著者: Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell - New England Journal of Medicine 2012 被引用: 3,784

  3. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

    著者: Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, Li‐Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Mairéad G. McNamara, Renata Zaucha, Antonio Avallone, Benjamin Tan, Juan Cundom, Choong‐kun Lee, Hidenori Takahashi, Masafumi Ikeda, Jen‐Shi Chen, Julie Wang, Mallory Makowsky, Nana Rokutanda, Philip He, John F. Kurland, Gordon Cohen, Juan W. Valle - NEJM Evidence 2022 被引用: 1,092

  4. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

    著者: Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler - New England Journal of Medicine 2019 被引用: 2,213

  5. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    著者: Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Tao Ji, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Arndt Vogel - The Lancet Oncology 2020 被引用: 1,575

  6. HER2-targeted therapies — a role beyond breast cancer

    著者: Do‐Youn Oh, Yung‐Jue Bang - Nature Reviews Clinical Oncology 2019 被引用: 1,071

  7. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik‐Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen‐Shi Chen, Li‐Yuan Bai, Sung‐Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku - The Lancet Oncology 2022 被引用: 768

  8. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Li‐Tzong Chen - The Lancet 2017 被引用: 2,279

  9. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

    著者: Sun Young Rha, Do‐Youn Oh, Patricio Yañez, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, M. Fernández, Jin Li, Maeve A. Lowery, Timuçin Çil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan Wyrwicz, Guillermo Méndez, Juan Manuel O’Connor, Alvaro Yanzi Castilla, Juan Cundom, Diego Kaen, Rachel Wong, Weng Ng, Morteza Aghmesheh, Mauricio Peressoni, Carlos Eduardo Mattos da Cunha Andrade, Fábio Franke, Gustavo R. Alves, Felipe Jose Cruz, Karina Vianna, Maria Marcela Monteiro, Michael J. Raphael, Scott Berry, Raymond Woo-Jun Jang, Ann Tan, Jamil Asselah, Patricio Yañez Weber, Mauricio Mahave, César Sánchez, Pamela Salman, Yuxian Bai, Jin Li, Xiaochun Zhang, Tianshu Liu, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Suxia Luo, Wěi Li, Jieer Ying, Xi Chen, Shan Zeng, Yanli Qu, Lin Yang, Lin Zhao, Ping Chen, Hongming Pan, Enxiao Li, Feng Ye, Jianwei Lu, Xinjun Liang, Qun Zhao, Xianli Yin, Junhe Li, Junhe Li, Guoqing Lv, Shouguo Li, Álvaro Guerrero, Juan Rubiano, M. Fernández, Ray Manneh Kopp, Adrián Guzmán Ramírez, Luis Corrales, Ileana Gonzalez Herrera, Bohuslav Melichar, Tomáš Büchler, Tomáš Svoboda, Radka Obermannová, David Vrána, Jakub Cvek, Per Pfeiffer, Lene Bæksgaard, Mette Yilmaz, Valérie Boige, Daniel López‐Trabada, Christophe Borg, Diane Pannier, Sandrine Hiret, Frédéric Di Fiore, Jean‐Philippe Metges, Dirk Arnold, Uwe M. Martens, Florian Lordick ほか 128 名 - The Lancet Oncology 2023 被引用: 622

  10. Biliary tract cancer

    著者: Juan W. Valle, Robin Katie Kelley, Bruno Nervi, Do‐Youn Oh, Andrew X. Zhu - The Lancet 2021 被引用: 1,012

  11. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

    著者: Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin Kate Kelley, Philippe A. Cassier, Heinz‐Josef Klümpen, Heung-Moon Chang, Li‐Tzong Chen, Josep Tabernero, Do‐Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel H. Ahn, Robert S. Epstein, Abdel‐Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John Bridgewater - New England Journal of Medicine 2023 被引用: 541

  12. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    著者: Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu - The Lancet Oncology 2020 被引用: 1,075

  13. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

    著者: Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani, Daniel J. Renouf, Myung Ah Lee, Weijing Sun, George A. Fisher, Aram F. Hezel, Shao-Chun Chang, Gordana Vlahovic, Osamu Takahashi, Yin Yang, David Fitts, Philip Agop Philip - JAMA Oncology 2019 被引用: 765

  14. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

    著者: Michele Maio, Paolo A. Ascierto, L. V. Manzyuk, Daniel Motola‐Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni M. Bariani, A. De Jesus Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller, Do‐Youn Oh, Maya Gottfried, Lei Xu, Fan Jin, Kevin Norwood, Aurélien Marabelle - Annals of Oncology 2022 被引用: 445

  15. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

    著者: Andrew X. Zhu, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-Fraile, Sung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Ghassan K. Abou‐Alfa - JAMA Oncology 2021 被引用: 473

  16. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

    著者: Eric Van Cutsem, Margaret A. Tempero, Darren Sigal, Do‐Youn Oh, Nicola Fazio, Teresa Macarulla, Erika Hitre, Pascal Hammel, Andrew Hendifar, Susan E. Bates, Chung‐Pin Li, Sunil R. Hingorani, Christelle de la Fouchardière, Anup Kasi, Volker Heinemann, Anthony Maraveyas, Nathan Bahary, Laura Layos, Vaibhav Sahai, Lei Zheng, Jill Lacy, Joon Oh Park, Fabienne Portales, Paul E. Oberstein, Wilson Wu, Dimitrios Chondros, Andrea J. Bullock, on behalf of the HALO 109-301 Investigators - Journal of Clinical Oncology 2020 被引用: 446

  17. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

    著者: James J. Harding, Jia Fan, Do‐Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui‐Chuan Sun, Teresa Macarulla, Feng Xie, Jean‐Philippe Metges, Jieer Ying, John Bridgewater, Myung Ah Lee, Mohamedtaki Abdulaziz Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip M. Garfin, Shubham Pant, Ghassan K. Abou‐Alfa, J. Adeva Alfonso, Massimo Aglietta, Ari David Baron, Muhammad Shaalan Beg, Paula Carrasco Aguirre, Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao - The Lancet Oncology 2023 被引用: 247

  18. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

    著者: Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Takashi Oshima, Nina Karaseva, M. A. Osipov, Hisateru Yasui, Hiroshi Yabusaki, S. G. Afanasyev, Young Kyu Park, Salah-Eddin Al-Batran, Takaki Yoshikawa, Patricio Yañez, Maria Di Bartolomeo, Sara Lonardi, Josep Tabernero, Eric Van Cutsem, Yelena Y. Janjigian, Do‐Youn Oh, Jianming Xu, Xiao Fang, Chie‐Schin Shih, Pooja Bhagia, Yung‐Jue Bang - The Lancet Oncology 2023 被引用: 339

  19. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

    著者: Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton, Do‐Youn Oh, Diana L. Hanna, Yoon‐Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabell, Sun Young Rha, José Mayordomo, Anthony B. El-Khoueiry, Shubham Pant, Kanwal Pratap Singh Raghav, Jin Won Kim, Amita Patnaik, Todd Gray, R. H. Davies, Mark A. Ozog, Joseph Woolery, Keun‐Wook Lee - The Lancet Oncology 2022 被引用: 182

  20. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

    著者: Do-Youn Oh, Kyung-Hun Lee, Dae-Won Lee, Jeesun Yoon, Tae-Yong Kim, Ju-Hee Bang, Ah-Rong Nam, Kyoung-Seok Oh, Jae-Min Kim, Young Lee, Violeta Guthrie, Patricia McCoon, Weimin Li, Song Wu, Qu Zhang, Marlon C Rebelatto, Jin Won Kim - ˜The œLancet. Gastroenterology & hepatology 2022 被引用: 314

  21. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    著者: James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel - The Lancet 2015 被引用: 1,264

  22. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

    著者: Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David R. Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Dişel, Roberto Pazo-Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui‐Hua Xu - BMJ 2024 被引用: 245

  23. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

    著者: Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L. Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria, Jaume Capdevila, Amparo García-Burillo, Do‐Youn Oh, Changhoon Yoo, Thorvardur R Halfdanarson, Stephen A. Falk, Ilya Folitar, Yufen Zhang, Paola Aimone, Wouter W. de Herder, Diego Ferone - The Lancet 2024 被引用: 324

  24. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

    著者: Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin Kate Kelley, Willeke Ros, Antoîne Italiano, Kazuhiko Nakagawa, Hope S. Rugo, Filippo de Braud, Andréa Varga, Aaron R. Hansen, Hui Wang, Suba Krishnan, Kevin Norwood, Toshihiko Doi - International Journal of Cancer 2020 被引用: 498